Skip to Content

Posts tagged with "Drug Industry History"

  • Drug Industry History

    C-Nucleosides Never Went Away

    Here’s a paper in J. Med. Chem. calling for a revival of work in the C-nucleoside area. To some extent, these compounds never went away, but it’s certainly true that there was a period where many more groups were working on them. When I was looking for an undergraduate research project to do during my… Read More
  • Cancer

    A Biotech Education, In Progress

    Peter Thiel is worth paying some attention to. And it’s not just because he’s a wealthy venture capitalist – his views on pharma and biotech research are worth noting because he’s an excellent example of an intelligent, motivated outsider, someone with a strong technical background who’s approaching drug discovery de n… Read More
  • Drug Industry History

    That One Big Answer

    This post by Wavefunction on the foxes-and-hedgehogs split in drug discovery is well worth reading. You may recall, via Isaiah Berlin and Archilochus, that a fox knows many things, while a hedgehog knows one big thing. Here’s how that can apply to the drug R&D business: Now drug discovery should be the poster boy for… Read More
  • Cancer

    ABT-199 Nears Its Finish Line

    A couple of years back, AbbVie ran into an unusual problem in the clinic. Their Bcl ligand, ABT-199, was working a bit too well, and killing off so many leukemia cells that the resulting cellular debris was causing kidney trouble in some patients. The company immediately started working on clinical protocols to get things restarted… Read More
  • Alzheimer's Disease

    On the FDA, Drug Approvals, and Not Knowing Enough

    It doesn’t seem to have generated many headlines, but the FDA recently released a report (PDF) on the pace of drug development. Titled “Targeted Drug Development: Why Are Many Diseases Lagging Behind”, it seems to be motivated, at least in part, by a desire to answer “Not Because of Us!” The agency goes into some deta… Read More
  • Business and Markets

    Celgene Expanding

    Readers who have worked in the NJ pharma world will be familiar with the big research campus in Summit. I go back far enough to remember it from my first round of job interviews, when it was still Ciba-Geigy. (I was on my post-doc in Germany at the time, and I’d already been asked if… Read More
  • Drug Assays

    The End of Compound Property Optimization Is At Hand

    Here’s another Big Retrospective Review of drug pipeline attrition. This sort of effort goes back to the now-famous Rule-of-Five work, and readers will recall the Pfizer roundup of a few years back, followed by an AstraZeneca one (which didn’t always recapitulate the Pfizer pfindings, either). This latest is a joint effort to look at th… Read More
  • Business and Markets

    Are Things Really Picking Up?

    Is the recent upturn in drug approvals the real thing? Years of overall decline would have to be overcome, but it would be good news if the industry has, in fact, picked back up again. A new article in Nature Reviews Drug Discovery</I. makes the case, based on a measure they're calling the "vintage index". Read More
  • Drug Development

    Hubris Watch

    I like scientific progress a lot. And we’ve had quite a bit of it in recent years in immunotherapy and gene editing; no one can doubt it. But there still seems to be something a bit off with the quotes below. These are the CEOs of Bluebird and Agios, speaking at the National Venture Capital… Read More
  • Drug Industry History

    Rename Merck. Either Merck.

    Ed Silverman at Pharmalot has a piece on a perennial source of confusion for anyone outside the drug industry (and too many inside it): the difference between Merck and Merck. One of them gets called “Merck-Darmstadt” or just “German Merck” by some people – I’ve never heard “Merck KGaA” used in spoken… Read More
...567...